(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 38.97% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.39%.
Harrow's revenue in 2026 is $272,303,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $13,343,498,569, with the lowest HROW revenue forecast at $12,788,775,965, and the highest HROW revenue forecast at $13,756,375,998. On average, 9 Wall Street analysts forecast HROW's revenue for 2027 to be $20,117,815,691, with the lowest HROW revenue forecast at $17,476,368,121, and the highest HROW revenue forecast at $22,536,257,328.
In 2028, HROW is forecast to generate $27,305,754,835 in revenue, with the lowest revenue forecast at $23,760,370,028 and the highest revenue forecast at $30,760,671,459.